2015
Non-Factor VIII Coagulation Proteins Fail to Predict Joint Outcome in Severe Hemophilia a
Warren B, Jacobsen L, Villalobos-Menuey E, Abshire T, Shapiro A, Recht M, Brown D, Leissinger C, Kempton C, Lane H, Nugent D, Manco-Johnson M. Non-Factor VIII Coagulation Proteins Fail to Predict Joint Outcome in Severe Hemophilia a. Blood 2015, 126: 2289. DOI: 10.1182/blood.v126.23.2289.2289.Peer-Reviewed Original ResearchVon Willebrand factor antigenThrombin-activatable fibrinolysis inhibitorEntity's Board of DirectorsTissue factor pathway inhibitorThrombin-antithrombin complexFactor V Leiden heterozygositySevere hemophilia A.Euglobulin lysis timeMRI scorePhysical exam scoresFactor VIIIEpisode groupV LeidenCSL BehringHemophilia A.Bleeding rateJoint bleedsThrombin-activatable fibrinolysis inhibitor levelsTreatment of severe hemophilia AActivated protein C resistanceHigh MRI scoreTotal MRI scoreCoagulation proteinsFactor VIII prophylaxisSevere hemophilia A
2014
Study of Associated Genetic Variants in Indian Subjects Reveals the Basis of Ethnicity Related Differences in Susceptibility to Venous Thromboembolism
Kumari B, Srivastava S, Chatterjee T, Vardhan R, Tyagi T, Gupta N, Sahu A, Chandra K, Ashraf M. Study of Associated Genetic Variants in Indian Subjects Reveals the Basis of Ethnicity Related Differences in Susceptibility to Venous Thromboembolism. Thrombosis 2014, 2014: 182762. PMID: 25349733, PMCID: PMC4198785, DOI: 10.1155/2014/182762.Peer-Reviewed Original ResearchProthrombin 20210G/AGenetic variantsAssociated genetic variantsTissue factor pathway inhibitorT mutationCandidate genesGenesMutationsPlasminogen activator inhibitor-1Protective variantsPathway inhibitorActivator inhibitor-1Inhibitor-1Susceptibility of individualsPCR-RFLPFactor pathway inhibitorSusceptibility of IndiansVariantsSusceptibilityMTHFR geneInhibitors
2003
Tissue factor pathway inhibitors as a novel approach to antithrombotic therapy.
Sajadi S, Ezekowitz MD, Dhond A, Netrebko P. Tissue factor pathway inhibitors as a novel approach to antithrombotic therapy. Drug News & Perspectives 2003, 16: 363-9. PMID: 12973447, DOI: 10.1358/dnp.2003.16.6.829308.Peer-Reviewed Original ResearchConceptsTissue factor pathway inhibitorFactor pathway inhibitorTissue factorPathway inhibitorNew antithrombotic approachComplications of atherosclerosisPathogenesis of atherosclerosisAntithrombotic therapyAntithrombotic approachEndothelial injurySystemic hemostasisNeointimal formationVascular interventionsAtherosclerotic plaquesEndothelial cellsInhibitory effectExtrinsic pathwayAtherosclerosisInhibitorsPlaquesCoagulationEarly stagesComplicationsFactorsAnticoagulants
1998
Hypotension and inflammatory cytokine gene expression triggered by factor Xa–nitric oxide signaling
Papapetropoulos A, Piccardoni P, Cirino G, Bucci M, Sorrentino R, Cicala C, Johnson K, Zachariou V, Sessa W, Altieri D. Hypotension and inflammatory cytokine gene expression triggered by factor Xa–nitric oxide signaling. Proceedings Of The National Academy Of Sciences Of The United States Of America 1998, 95: 4738-4742. PMID: 9539808, PMCID: PMC22560, DOI: 10.1073/pnas.95.8.4738.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCells, CulturedCytokinesEndothelium, VascularFactor XaFibrinogenGene Expression RegulationHistamineHumansHypotensionInflammationInterleukin-6MaleNG-Nitroarginine Methyl EsterNitric OxidePolymerase Chain ReactionRatsRats, WistarSplanchnic CirculationStereoisomerismTumor Necrosis Factor-alphaUmbilical VeinsConceptsEffector cell protease receptor-1Cytokine gene expressionFactor XaReceptor 1NO synthase inhibitor LNitric oxideInflammatory cytokine gene expressionActivation of coagulationNitroarginine methyl esterEndothelial cell releaseTissue factor pathway inhibitorAcute phase responseEndothelial cell ligandsThrombin inhibitor hirudinInterleukin-6 mRNAFactor pathway inhibitorDose-dependent mannerVascular endothelial cellsL-NAMED-NAMEGrowth factor peptidesInterleukin-6Dose-dependent reactionCell ligandsPathway inhibitorAncylostoma caninum Anticoagulant Peptide Blocks Metastasis In Vivo and Inhibits Factor Xa Binding to Melanoma Cells In Vitro
Donnelly K, Bromberg M, Milstone A, Madison McNiff J, Terwilliger G, Konigsberg W, Cappello M. Ancylostoma caninum Anticoagulant Peptide Blocks Metastasis In Vivo and Inhibits Factor Xa Binding to Melanoma Cells In Vitro. Thrombosis And Haemostasis 1998, 79: 1041-1047. PMID: 9609244, DOI: 10.1055/s-0037-1615117.Peer-Reviewed Original ResearchConceptsAnti-metastatic activityThrombin generationAntimetastatic effectFactor XaEffector cell protease receptor-1Melanoma cellsTissue factor pathway inhibitorDose-dependent reductionFactor pathway inhibitorHuman coagulation factor XaHuman melanoma cellsFactor V/VaPulmonary metastasesSubcutaneous injectionSCID miceCoagulation factor XaVein injectionBlock metastasisReceptor 1Inhibits factor XaPathway inhibitorTumor cellsXa concentrationsProthrombinase activityPotential mechanisms
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply